Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Clinical trial NCT02304458 · COMPLETED

Trial details

NCT number: NCT02304458
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Metastatic Melanoma Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Recurrent Hodgkin Lymphoma Recurrent Malignant Solid Neoplasm Recurrent Melanoma Recurrent Neuroblastoma Recurrent Non-Hodgkin Lymphoma Recurrent Osteosarcoma Recurrent Rhabdomyosarcoma Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Refractory Hodgkin Lymphoma Refractory Malignant Solid Neoplasm

Start date: 2015-03-30
Primary completion: 2021-09-30
Enrollment: 140

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.